title: Patients with endometriosis and patients with poor ovarian reserve have abnormal follicle-stimulating hormone receptor signaling pathways.
abstract: OBJECTIVE
  To study the integrity of the FSH receptor (FSHR) signaling pathway in granulosa-lutein cells at the time of egg retrieval and its relationship with the infertility diagnosis.
  
  
  METHODS
  In vitro assays.
  
  
  METHODS
  University laboratory and private IVF center.
  
  
  METHODS
  Patients undergoing IVF: 35 controls (no ovarian factor, NOF), 28 poor responders (PR), 32 patients with endometriosis (EM), and 22 patients with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Quantitative reverse transcriptase-polymerase chain reaction (PCR) in granulosa-lutein cells from pooled follicles.
  
  
  METHODS
  Correlation between expression of FSHR and FSH-regulated genes PAPP/Cyp19A1.
  
  
  RESULTS
  Positive correlations among FSHR, PAPP, and Cyp19A1 expression levels are observed in NOF and are lost, with different patterns, in poor responder patients and those with endometriosis. Patients with endometriosis are an heterogeneous group including patients with poor ovarian reserve who behave like other poor responders patients (endometriosis-A) and patients with good response to ovarian stimulation (endometriosis-B) who show a specific alteration of the FSHR signaling pathway.
  
  
  CONCLUSIONS
  These preliminary data suggest that the different signaling pathways activated through the FSHR in normal ovaries (NOF) are disrupted in poor responders and in patients with endometriosis. A better knowledge of the molecular origin of these errors may guide clinicians in the choice of personalized ovulation induction protocols for each type of ovarian dysfunction.
authors.affiliation: Departamento de Bioquímica y Biología Molecular, Universidad de la Laguna, Tenerife, Spain.
authors.forename: Rebeca
authors.initials: R
authors.lastname: González-Fernández
authors.forename: Óscar
authors.initials: Ó
authors.lastname: Peña
authors.forename: Jairo
authors.initials: J
authors.lastname: Hernández
authors.forename: Pablo
authors.initials: P
authors.lastname: Martín-Vasallo
authors.forename: Angela
authors.initials: A
authors.lastname: Palumbo
authors.forename: Julio
authors.initials: J
authors.lastname: Ávila
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D001141:Aromatase / Q000235:genetics; D016022:Case-Control Studies; D004715:Endometriosis / Q000150:complications* / Q000235:genetics / Q000503:physiopathology; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage; D005307:Fertilization in Vitro; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000235:genetics* / Q000503:physiopathology / Q000628:therapy; D008184:Luteal Cells / Q000187:drug effects / Q000378:metabolism*; D054315:Oocyte Retrieval; D010060:Ovulation / Q000187:drug effects / Q000235:genetics*; D010062:Ovulation Induction / Q000379:methods; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000235:genetics / Q000503:physiopathology; D011266:Pregnancy-Associated Plasma Protein-A / Q000235:genetics; D011962:Receptors, FSH / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics*; D013030:Spain
chemical_list: D005300:Fertility Agents, Female; D011962:Receptors, FSH; D001141:Aromatase; D011266:Pregnancy-Associated Plasma Protein-A